Trade Ultragenyx Pharmaceutical Inc - RARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.13 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 56.38 |
| Open | 56.49 |
| 1-Year Change | 48.66% |
| Day's Range | 54.64 - 56.49 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 6, 2024 | 55.18 | -0.69 | -1.24% | 55.87 | 56.84 | 54.61 |
| Sep 5, 2024 | 56.38 | 0.28 | 0.50% | 56.10 | 57.17 | 55.57 |
| Sep 4, 2024 | 56.07 | 1.14 | 2.08% | 54.93 | 56.51 | 54.85 |
| Sep 3, 2024 | 55.65 | -0.29 | -0.52% | 55.94 | 57.52 | 54.87 |
| Aug 30, 2024 | 56.69 | -0.24 | -0.42% | 56.93 | 57.48 | 55.90 |
| Aug 29, 2024 | 56.86 | -0.42 | -0.73% | 57.28 | 58.60 | 56.58 |
| Aug 28, 2024 | 57.72 | 0.66 | 1.16% | 57.06 | 58.17 | 56.90 |
| Aug 27, 2024 | 57.55 | 1.35 | 2.40% | 56.20 | 57.69 | 56.20 |
| Aug 26, 2024 | 57.00 | 0.25 | 0.44% | 56.75 | 58.09 | 56.46 |
| Aug 23, 2024 | 56.65 | 0.15 | 0.27% | 56.50 | 57.42 | 55.92 |
| Aug 22, 2024 | 56.25 | -0.65 | -1.14% | 56.90 | 57.98 | 55.96 |
| Aug 21, 2024 | 56.99 | 3.96 | 7.47% | 53.03 | 57.03 | 53.03 |
| Aug 20, 2024 | 52.94 | -0.34 | -0.64% | 53.28 | 53.58 | 52.54 |
| Aug 19, 2024 | 53.66 | 0.60 | 1.13% | 53.06 | 53.95 | 52.46 |
| Aug 16, 2024 | 53.01 | 1.60 | 3.11% | 51.41 | 53.18 | 51.17 |
| Aug 15, 2024 | 51.65 | -0.38 | -0.73% | 52.03 | 52.48 | 51.22 |
| Aug 14, 2024 | 51.68 | -0.06 | -0.12% | 51.74 | 51.86 | 51.03 |
| Aug 13, 2024 | 51.73 | 1.11 | 2.19% | 50.62 | 51.96 | 50.58 |
| Aug 12, 2024 | 50.87 | 0.88 | 1.76% | 49.99 | 51.30 | 49.06 |
| Aug 9, 2024 | 50.00 | 0.30 | 0.60% | 49.70 | 50.53 | 49.25 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ultragenyx Company profile
About Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.
Equity composition
Common Stock, $0.001 Par, 01/14, Auth. 250M Shares., 29,061,871 issd,. Insiders owns approx. 19.82%.
| Industry: | Bio Therapeutic Drugs |
60 Leveroni Ct
NOVATO
CALIFORNIA 94949
US
News
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com